Diabetic Nephropathy Global Clinical Trials Review, H2, 2017
- GDHC4384CTIDB
- Pages: 317
- July 2017
- Total Views:1165
- Region : Global
- GlobalData
- Market Research Report
Details
Diabetic Nephropathy Global Clinical Trials Review, H2, 2017
Summary
GlobalData's clinical trial report, "Diabetic Nephropathy Global Clinical Trials Review, H2, 2017" provides an overview of Diabetic Nephropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global clinical trials landscape
Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
The Report provides enrollment trends for the past five years
Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
Assists in formulating key business strategies with regards to investment
Helps in identifying prominent locations for conducting clinical trials which saves time and cost
Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
Supports understanding of trials count and enrollment trends by country in global therapeutics market
Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table Of Content
Scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials 22
Clinical Trials by Phase in E7 Countries 24
Clinical Trials in E7 Countries by Trial Status 25
Clinical Trials by Phase 27
In Progress Trials by Phase 28
Clinical Trials by Trial Status 29
Clinical Trials by End Point Status 31
Subjects Recruited Over a Period of Time 32
Clinical Trials by Sponsor Type 33
Prominent Sponsors 34
Top Companies Participating in Diabetic Nephropathy Therapeutics Clinical Trials 36
Prominent Drugs 38
Latest Clinical Trials News on Diabetic Nephropathy 39
Jun 26, 2017: MNK H.P. Acthar Gel DN Trial Results Alert 39
Jun 12, 2017: Prometic Life Sciences Present Data on PBI-4547 at 2017 American Diabetes Association 77th Scientific Sessions 39
May 19, 2017: MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers 39
Clinical Trial Profile Snapshots 40
Appendix 315
Abbreviations 315
Definitions 315
Research Methodology 316
Secondary Research 316
About GlobalData 317
Contact Us 317
Source 317
List Of Figure
List of Figures
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
Diabetic Nephropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Diabetic Nephropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
Diabetic Nephropathy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
Diabetic Nephropathy Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
Diabetic Nephropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 15
Diabetic Nephropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16
Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017* 17
Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017* 22
Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24
Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Phase (%), 2017* 27
Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 28
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Trial Status, 2017* 29
Diabetic Nephropathy Therapeutics Clinical Trials, Global, by End Point Status, 2017* 31
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 32
Diabetic Nephropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 33
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 34
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 36
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 38
GlobalData Methodology 316
List Of Table
List of Tables
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Region, 2017* 8
Diabetic Nephropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Diabetic Nephropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
Diabetic Nephropathy Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
Diabetic Nephropathy Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
Diabetic Nephropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 15
Diabetic Nephropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16
Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017* 18
Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 21
Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017* 23
Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24
Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 26
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Phase, 2017* 27
Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 28
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Trial Status, 2017* 30
Diabetic Nephropathy Therapeutics Clinical Trials, Global, by End Point Status, 2017* 31
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 32
Diabetic Nephropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 33
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 35
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 37
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 38
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Diabetic Nephropathy Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Diabetic Nephropathy, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania
Companies
Pfizer Inc
Eli Lilly and Company
Novartis AG
Mitsubishi Chemical Holdings Corp
Daiichi Sankyo Company Ltd
Steno Diabetes Center A/S
Bayer AG
C. H. Boehringer Sohn AG & Co KG
AbbVie Inc
NephroGenex Inc
Company Profile
Company Profile Title
Diabetic Nephropathy Global Clinical Trials Review, H2, 2017
Summary
GlobalData's clinical trial report, "Diabetic Nephropathy Global Clinical Trials Review, H2, 2017" provides an overview of Diabetic Nephropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global clinical trials landscape
Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
The Report provides enrollment trends for the past five years
Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
Assists in formulating key business strategies with regards to investment
Helps in identifying prominent locations for conducting clinical trials which saves time and cost
Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
Supports understanding of trials count and enrollment trends by country in global therapeutics market
Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials 22
Clinical Trials by Phase in E7 Countries 24
Clinical Trials in E7 Countries by Trial Status 25
Clinical Trials by Phase 27
In Progress Trials by Phase 28
Clinical Trials by Trial Status 29
Clinical Trials by End Point Status 31
Subjects Recruited Over a Period of Time 32
Clinical Trials by Sponsor Type 33
Prominent Sponsors 34
Top Companies Participating in Diabetic Nephropathy Therapeutics Clinical Trials 36
Prominent Drugs 38
Latest Clinical Trials News on Diabetic Nephropathy 39
Jun 26, 2017: MNK H.P. Acthar Gel DN Trial Results Alert 39
Jun 12, 2017: Prometic Life Sciences Present Data on PBI-4547 at 2017 American Diabetes Association 77th Scientific Sessions 39
May 19, 2017: MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers 39
Clinical Trial Profile Snapshots 40
Appendix 315
Abbreviations 315
Definitions 315
Research Methodology 316
Secondary Research 316
About GlobalData 317
Contact Us 317
Source 317
List Of Figure
List of Figures
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
Diabetic Nephropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Diabetic Nephropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
Diabetic Nephropathy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
Diabetic Nephropathy Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
Diabetic Nephropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 15
Diabetic Nephropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16
Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017* 17
Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017* 22
Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24
Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Phase (%), 2017* 27
Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 28
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Trial Status, 2017* 29
Diabetic Nephropathy Therapeutics Clinical Trials, Global, by End Point Status, 2017* 31
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 32
Diabetic Nephropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 33
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 34
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 36
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 38
GlobalData Methodology 316
List Of Table
List of Tables
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Region, 2017* 8
Diabetic Nephropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Diabetic Nephropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
Diabetic Nephropathy Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
Diabetic Nephropathy Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
Diabetic Nephropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 15
Diabetic Nephropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16
Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017* 18
Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 21
Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017* 23
Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24
Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 26
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Phase, 2017* 27
Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 28
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Trial Status, 2017* 30
Diabetic Nephropathy Therapeutics Clinical Trials, Global, by End Point Status, 2017* 31
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 32
Diabetic Nephropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 33
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 35
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 37
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 38
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Diabetic Nephropathy Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Diabetic Nephropathy, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania
Companies
Pfizer Inc
Eli Lilly and Company
Novartis AG
Mitsubishi Chemical Holdings Corp
Daiichi Sankyo Company Ltd
Steno Diabetes Center A/S
Bayer AG
C. H. Boehringer Sohn AG & Co KG
AbbVie Inc
NephroGenex Inc
: +91 9015378249
Related Reports
Page 157 | 
June 2021
Page 130 | December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020